Sort   by:  
 Page size 
UnknownAberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.
Not available
S-EPMC8387438 | biostudies-literature
MetabolomicsIAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function
The islet in type 2 diabetes (T2D) is characterized by amyloid deposits derived from islet amyloid polypeptide (IAPP), a protein co-expressed with insulin by β-cells. In common with amyloidogenic proteins implicated in neurodegeneration, human IAPP (hIAPP) forms membrane permeant toxic oligomers imp...
2020-04-17 | MTBLS951 | MetaboLights
TranscriptomicsMolecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres
Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by ptosis, dysphagia and proximal limb weakness. Autosomal-dominant OPMD is caused by a short (GCG)8–13 expansions within the first exon of the poly(A)-binding protein nuclear 1 gene (PABPN1), leading to an expanded p...
ORGANISM(S): Mus musculus 
2011-01-14 | E-GEOD-26604 | biostudies-arrayexpress
GenomicsThe Natural History of Human Prostate Cancer - samples
Affymetrix SNP6.0 genotype data for prostate cancer patients
EGAD00010000498 | EGA
GenomicsCRUK-ICGC Prostate Cancer Group Study
Prostate cancer somatic genomic sequencing data generated from 2011 onwards under auspices of the International Cancer Genome Consortium Prostate Cancer UK consortium (CRUK-ICGC Prostate Group), co-led by Colin Cooper and Ros Eeles, with other Principal Investigators (Brewer, Neal, Bova, McDermott, ...
EGAS00001000262 | EGA
GenomicsEGAS00001000262-sc-20170314 - samples
Whole Genome Sequencing Illumina HiSeq data from 111 men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy (target sequencing depth 50X) with matched blood control (target sequencing depth 30X). This data is from batches 4 to 6.
EGAD00001003225 | EGA
GenomicsEGAS00001000262-sc-20180521 - samples
Data collected as part of the Normal prostatectomy project analysis. Whole genome sequencing (WGS, targeted at 30X for normal tissue and 50X for tumour tissue) was performed on morphologically normal tissue samples from 30 patients with prostate cancer. In addition, seven prostate tissue samples wer...
EGAD00001004125 | EGA
GenomicsEGAS00001000262-sc-20141219 - samples
Whole Genome Sequencing Illumina HiSeq data from 95 men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy (target sequencing depth 50X) with matched blood control (target sequencing depth 30X). This data is from batches 1 to 3 and is the bulk of the data used in ...
EGAD00001001116 | EGA
GenomicsEGAS00001000262-sc-20140722b - samples
Whole Genome Sequencing Illumina HiSeq data from 20 men with prostate cancer. 20 samples were taken from primary tissue obtained at prostatectomy (target sequencing depth 50X) with matched blood control (target sequencing depth 30X). These were submitted for use in the ICGC Pan-Cancer Analysis of Wh...
EGAD00001000892 | EGA
GenomicsEGAS00001000262-sc-2023-03-27T08:52:54Z - samples
This dataset includes Illumina EPIC Capture Sequencing Data of 376 samples from 188 men with prostate cancer. Samples were taken from primary tissue obtained at prostatectomy, with matched pathologically assessed non-cancer control material. This DNA methylation data includes donors and samples incl...
EGAD00001010184 | EGA
Sort   by:  
 Page size